Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C25H34F2O6 |
| Molecular Weight | 468.5307 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 10 / 10 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@]3([H])[C@]4([H])C[C@H](F)C5=CC(=O)CC[C@]5(C)[C@@]4(F)[C@@H](O)C[C@]3(C)[C@@]1(O[C@H](CCC)O2)C(=O)CO
InChI
InChIKey=IXTCZMJQGGONPY-XJAYAHQCSA-N
InChI=1S/C25H34F2O6/c1-4-5-21-32-20-10-14-15-9-17(26)16-8-13(29)6-7-22(16,2)24(15,27)18(30)11-23(14,3)25(20,33-21)19(31)12-28/h8,14-15,17-18,20-21,28,30H,4-7,9-12H2,1-3H3/t14-,15-,17-,18-,20+,21+,22-,23-,24-,25+/m0/s1
Rofleponide is a third generation synthetic glucocorticosteroid. This compound has high affinity for the rat thymus glucocorticoid receptor and showed a very high biotransformation rate in the human liver. Rofleponide was being investigated for its anti-inflammatory, immunosuppressive and anti-anaphylactic activity. It was evaluated in phase II clinical trials for its safety and efficacy in allergic rhinitis and asthma, and in a preclinical study for use in inflammatory bowel disease, but development of this drug was discontinued. Rofleponide was never marketed.
Originator
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C521
Created by
admin on Sat Dec 16 15:48:30 GMT 2023 , Edited by admin on Sat Dec 16 15:48:30 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C77006
Created by
admin on Sat Dec 16 15:48:30 GMT 2023 , Edited by admin on Sat Dec 16 15:48:30 GMT 2023
|
PRIMARY | |||
|
7256
Created by
admin on Sat Dec 16 15:48:30 GMT 2023 , Edited by admin on Sat Dec 16 15:48:30 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107134
Created by
admin on Sat Dec 16 15:48:30 GMT 2023 , Edited by admin on Sat Dec 16 15:48:30 GMT 2023
|
PRIMARY | |||
|
SUB10357MIG
Created by
admin on Sat Dec 16 15:48:30 GMT 2023 , Edited by admin on Sat Dec 16 15:48:30 GMT 2023
|
PRIMARY | |||
|
R9IQ7GVL3E
Created by
admin on Sat Dec 16 15:48:30 GMT 2023 , Edited by admin on Sat Dec 16 15:48:30 GMT 2023
|
PRIMARY | |||
|
DTXSID601318252
Created by
admin on Sat Dec 16 15:48:30 GMT 2023 , Edited by admin on Sat Dec 16 15:48:30 GMT 2023
|
PRIMARY | |||
|
3055174
Created by
admin on Sat Dec 16 15:48:30 GMT 2023 , Edited by admin on Sat Dec 16 15:48:30 GMT 2023
|
PRIMARY | |||
|
Rofleponide
Created by
admin on Sat Dec 16 15:48:30 GMT 2023 , Edited by admin on Sat Dec 16 15:48:30 GMT 2023
|
PRIMARY | |||
|
144459-70-1
Created by
admin on Sat Dec 16 15:48:30 GMT 2023 , Edited by admin on Sat Dec 16 15:48:30 GMT 2023
|
PRIMARY | |||
|
100000080271
Created by
admin on Sat Dec 16 15:48:30 GMT 2023 , Edited by admin on Sat Dec 16 15:48:30 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
PRODRUG (METABOLITE ACTIVE)
